Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Peters, S; Paz-Ares, LG; Reck, M; Carbone, DP; Brahmer, JR; Borghaei, H; Lu, S; O’Byrne, KJ; John, T; Ciuleanu, TE; Schenker, M; Caro, RB; Nishio, M; Cobo, M; Lee, JS; Zurawski, B; Pluzanski, A; Aoyama, T; Tschaika, M; Devas, V; Grootendorst, DJ; Ramalingam, SS – 2025 – 10.1016/j.jtho.2024.09.1439